193012-35-0

Usage

Chemical class

Benzimidazole derivative
A benzimidazole is a heterocyclic aromatic organic compound that consists of a 5-membered ring with two nitrogen atoms.

Substituents

Dichlorophenylmethyl and 2-methyl groups
The dichlorophenylmethyl group consists of a phenyl ring with two chlorine atoms attached, which can influence the compound's chemical reactivity and properties.

Sulfonyl group

Pentylsulfonyl

Potential applications

Pharmaceuticals and drug development
The compound has been studied for its potential as an antifungal agent, and it may have other therapeutic properties as well.

Research focus

Medicinal chemistry
The chemical structure and properties of 1H-Benzimidazole-6-carboxamide, 1-[(2,4-dichlorophenyl)methyl]-2-methyl-N-(pentylsulfonyl)make it a promising candidate for further research and development in the field of medicinal chemistry.

Upstream product

• 193010-16-1 6-carboxy-1-(2,4-dichlorobenzyl)-2-methylbenzimidazole> 
• 52960-14-2 1-pentylsulfonamide 
• 6674-22-2 1,8-diazabicyclo[5.4.0]undec-7-ene 
• 530-62-1 1,1'-carbonyldiimidazole 

Relevant academic research and scientific papers

Benzimidazole compounds

A benzimidazole compound represented by the formula (I): wherein R3is a carboxyl group, a esterified carboxyl group, an amidated carboxyl group, an amino group, an amido group, or a sulfonyl group, or their pharmaceutically acceptable salts. Because of their blood sugar-depressing effect or PDE5 inhibitory effect, these compounds or salts thereof are useful as medicines for treating impaired glucose tolerance, diabetes, diabetic complications, syndrome of insulin resistance, hyperlipidemia, atherosclerosis, cardiovascular disorders, hyperglycemia, or hypertension; or stenocardia, hypertension, pulmonary hypertension, congestive heart failure, glomerulopathy, tubulointerstitial disorders, renal failure, atherosclerosis, angiostenosis, distal angiopathy, cerebral apoplexy, chronic reversible obstructions, allergic rhinitis, urticaria, glaucoma, diseases characterized by enteromotility disorders, impotence, diabetic complications, nephritis, cancerous cachexia, or restenosis after PTCA.

Method of inhibiting neoplastic cells with benzimidazole derivatives

A method for inhibiting neoplasia, particularly cancerous and precancerous lesions by exposing the affected cells to benzimidazole derivatives.

REMEDIES FOR POLYCYSTIC OVARY SYNDROME

The present invention relates to a therapeutic agent for polycystic ovary syndrome, which comprises a compound of the following formula (1) or (2), or a pharmaceutically acceptable salt thereof as an active ingredient: wherein each symbol is as defined in the specification.

Benzimidazole derivatives

PCT No. PCT/JP96/03858 Sec. 371 Date Nov. 2, 1998 Sec. 102(e) Date Nov. 2, 1998 PCT Filed Dec. 27, 1996 PCT Pub. No. WO97/24334 PCT Pub. Date Jul. 10, 1997Novel benzimidazole derivatives represented by the formula (I): wherein R3 is a carboxyl group, a esterified carboxyl group, an amidated carboxyl group, an amino group, an amido group, or a sulfonyl group, or their pharmaceutically acceptable salts. Because of their blood sugar-depressing effect or PDE5 inhibitory effect, these compounds or salts thereof are useful as medicines for treating impaired glucose tolerance, diabetes, diabetic complications, syndrome of insulin resistance, hyperlipidemia, atherosclerosis, cardiovascular disorders, hyperglycemia, or hypertension; or stenocardia, hypertension, pulmonary hypertension, congestive heart failure, glomerulopathy, tubulointerstitial disorders, renal failure, atherosclerosis, angiostenosis, distal angiopathy, cerebral apoplexy, chronic reversible obstructions, allergic rhinitis, urticaria, glaucoma, diseases characterized by enteromotility disorders, impotence, diabetic complications, nephritis, cancerous cachexia, or restenosis after PTCA.